X-group (possible homology)

62 Carbonic anhydrase

Open in classification tree →

Ligands and drugs

2,147

Member domains

1,880

with ligand contacts (≤ 4 Å)

87.6% of members

1,651

with DrugDomain annotations

76.9% of members

1,032

with a DrugBank compound

48.1% of members

Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.

Chemical profile

ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.

Proteins with classified ligands

Superclasses bound (of 23)

12.9

Superclasses per 20 proteins

broader than 100% of the 256 X-groups with enough proteins to compare (median 7.6)

The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.

Superclass	Proteins	Expected	Ratio	Significance
Organoheterocyclic compounds	21	5.2	4.07×	q < 0.0001
Homogeneous non-metal compounds	15	7.2	2.08×	q = 5.7e-3
Homogeneous metal compounds	30	16.5	1.82×	q < 0.0001
Organic oxygen compounds	10	6.7	1.50×	q = 0.26
Organic acids and derivatives	7	5.2	1.35×	q = 0.42
Nucleosides, nucleotides, and analogues	1	9.3	0.11×	q = 1.0e-3
Hydrocarbon derivatives	1	0.0	35×	not tested
Organic salts	1	0.0	29×	not tested
Organometallic compounds	1	0.1	21×	not tested
Organohalogen compounds	1	0.1	10×	not tested
Organosulfur compounds	6	0.7	8.70×	not tested
Phenylpropanoids and polyketides	4	0.7	5.74×	not tested
Benzenoids	12	2.5	4.90×	not tested
Organic nitrogen compounds	2	1.1	1.87×	not tested
Mixed metal/non-metal compounds	1	0.7	1.42×	not tested
Lipids and lipid-like molecules	1	3.7	0.27×	not tested

enriched (q < 0.05)depleted (q < 0.05)not significantnot tested (expected < 5)

Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.

DrugBank compounds

DrugBank	PDB ligand	Name	Domains
DB03975	MBO	Mercuribenzoic Acid	77
DB00819	AZM	Acetazolamide	75
DB03709	BCN	Bicine	50
DB02379	BGC	Beta-D-Glucose	27
DB00141	NAG	N-Acetylglucosamine	23
DB09157	CO2	Carbon dioxide	23
DB01671	HGB	p-Hydroxymercuribenzoic acid	21
DB00311	EZL	Ethoxzolamide	19
DB02831	2HP	Dihydrogenphosphate	16
DB00909	—	Zonisamide	15
DB08846	—	Ellagic acid	11
DB00869	ETS	Dorzolamide	9
DB07050	D8W	Benzolamide	9
DB00273	TOR	Topiramate	8
DB01194	BZ1	Brinzolamide	8
DB03345	BME	Mercaptoethanol	8
DB03793	BEZ	Benzoic acid	8
DB03385	4MZ	4-Methylimidazole	7
DB00774	—	Hydroflumethiazide	6
DB00562	—	—	5

Most frequently bound compounds

PDB ligand	Name	Domains in contact
ZNmetal	ZINC ION	1,811
HGmetal	MERCURY (II) ION	154
MBO	MERCURIBENZOIC ACID	81
CL	CHLORIDE ION	80
AZM	5-ACETAMIDO-1,3,4-THIADIAZOLE-2-SULFONAMIDE	75
NAmetal	SODIUM ION	63
BCN	BICINE	54
BE7	(4-CARBOXYPHENYL)(CHLORO)MERCURY	51
CO2	CARBON DIOXIDE	31
BGC	beta-D-glucopyranose	27
HGB	4-(HYDROXYMERCURY)BENZOIC ACID	23
NAG	2-acetamido-2-deoxy-beta-D-glucopyranose	23
GLC	alpha-D-glucopyranose	20
V14	3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide	18
CAmetal	CALCIUM ION	17
EZL	6-ethoxy-1,3-benzothiazole-2-sulfonamide	17
MZM	N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3H)-ylidene)acetamide	17
NImetal	NICKEL (II) ION	17
2HP	DIHYDROGENPHOSPHATE ION	16
COmetal	COBALT (II) ION	15